Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.57 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.54 |
| ▸ | TSHR | P16473 | 2/20 | 0.54 |
| ▸ | GAA | P10253 | 2/20 | 0.52 |
| ▸ | MEN1 | O00255 | 6/20 | 0.51 |
| ▸ | KMT2A | Q03164 | 6/20 | 0.51 |
| ▸ | POLB | P06746 | 1/20 | 0.51 |
| ▸ | MAPT | P10636 | 2/20 | 0.49 |
| ▸ | TP53 | P04637 | 1/20 | 0.49 |
| ▸ | LMNA | P02545 | 1/20 | 0.49 |
| ▸ | RAB9A | P51151 | 1/20 | 0.49 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.48 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.48 |
| ▸ | HPGD | P15428 | 1/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3974796 | 0.80 | SMN1; SMN2 (0.64) | SMN1; SMN2ALOX15TSHRGAAMEN1 | |
| Hydrochloric Acid SCHEMBL4087801 | 0.79 | SMN1; SMN2 (0.62) | SMN1; SMN2ALOX15TSHRGAAMEN1 | |
| SCHEMBL8559004 | 0.72 | RAB9A (0.65) | SMN1; SMN2ALOX15TSHRGAAMEN1 | |
| SCHEMBL31703144 | 0.71 | ALOX15 (1.00) | SMN1; SMN2ALOX15TSHRGAAMEN1 | |
| SCHEMBL13799881 | 0.71 | ALOX15 (1.00) | SMN1; SMN2ALOX15TSHRGAAMEN1 | |
| SCHEMBL8243795 | 0.70 | ALDH1A1 (0.66) | SMN1; SMN2ALOX15TSHRGAAMEN1 | |
| SCHEMBL24000528 | 0.69 | ENPP1 (0.60) | ALOX15TSHRGAAMEN1KMT2A | |
| SCHEMBL8555258 | 0.69 | ALDH1A1 (0.73) | SMN1; SMN2ALOX15TSHRGAAMEN1 | |
| SCHEMBL24000789 | 0.69 | TSHR (0.50) | ALOX15TSHRGAAMEN1KMT2A | |
| SCHEMBL14554544 | 0.69 | MAOB (0.49) | SMN1; SMN2GAA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20220213122-A1 | SUBSTITUTED 1,6-DIHYDROPYRIDINONES AND 1,2-DIHYDROISOQUINOLINONES AS BET INHIBITORS | NUVATION BIO INC (US) | 2022-07-07 | — | — | US | disclosed |
| US-11192900-B2 | Substituted 1,6-dihydropyridinones and 1,2-dihydroisoquinolinones as bet inhibitors | NUVATION BIO INC. (US) | 2021-12-07 | — | — | US | disclosed |
| US-20200140459-A1 | HETEROCYCLIC COMPOUNDS AS BET INHIBITORS | SAGARD HOLDINGS MANAGER LP, AS ADMINISTRATIVE AGENT (CA) | 2020-05-07 | — | — | US | disclosed |
| WO-2009051504-A1 | BENZO- AND PYRIDOPYRIDAZINONES WITH ANALGESIC AND ANTIINFLAMMATORY ACTIVITY | UNIWERSYTET LODSKI (PL) | 2009-04-23 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220213122-A1 | SUBSTITUTED 1,6-DIHYDROPYRIDINONES AND 1,2-DIHYDROISOQUINOLINONES AS BET INHIBITORS | BET1, BRD4, BRD3 | SMN1; SMN2 2183/4885ALOX15 4564/4885TSHR 3214/4885 |
| US-20200140459-A1 | HETEROCYCLIC COMPOUNDS AS BET INHIBITORS | BET1, BRD4, BRD3 | SMN1; SMN2 2600/4885ALOX15 4089/4885TSHR 3306/4885 |
| US-11192900-B2 | Substituted 1,6-dihydropyridinones and 1,2-dihydroisoquinolinones as bet inhibitors | BET1, BRD4, PHKB | SMN1; SMN2 1773/4885ALOX15 4373/4885TSHR 3774/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.